Dr. Filer's history of advocacy for transformative care will
help Pelvital in its mission to revolutionize the standard of care
for UI
EAGAN,
Minn., May 9, 2024 /PRNewswire-PRWeb/ --
Pelvital, the women's health MedTech company on a mission to
transform the standard of care for urinary incontinence, is pleased
to announce the election of Wanda
Filer, MD, MBA, FAAFP, to its Board of Directors as an
independent director, effective April 29,
2024. Dr. Filer brings a wealth of leadership experience in
clinical family medicine practice, health and public policy, and
national advocacy for transformative care and underserved
populations.
Dr. Filer's commitment to improving healthcare access and
outcomes aligns with Pelvital's mission to provide accessible,
clinically proven solutions for pelvic health disorders, as
evidenced by Flyte, the company's novel FDA-cleared conservative
treatment for stress urinary incontinence and weakened pelvic floor
muscles. With her extensive background in business, healthcare, and
healthcare policy, Dr. Filer will be instrumental as Pelvital
advocates to improve women's health by instituting proactive
incontinence screenings and proactive conservative treatment as
standard in OB/GYN, family medicine, and primary care
practices.
Dr. Filer shared her excitement about joining Pelvital's Board
of Directors. "I am honored to join Pelvital's board and deeply
energized by this transformative opportunity to improve the lives
of the 62% of women suffering from urinary incontinence, and in so
doing, also reduce the significant comorbidities and downstream
effects of UI," she said. "The only way to impact the immediate and
downstream effects of UI at scale is to address it proactively and
upstream. Family medicine, primary care, and OB/GYN practitioners
have both a responsibility and an opportunity here to positively
impact individual women, public health, and the cost of care."
"We are thrilled to welcome Dr. Filer to Pelvital's Board of
Directors," says Lydia Zeller, CEO
and President of Pelvital. "With her vast experience and deep
understanding of the healthcare ecosystem, she will provide
invaluable guidance as we work on multiple fronts to increase
access to high value, effective care and change the paradigm for
incontinence."
Dr. Filer recently retired as Chief Medical Officer at VaxCare,
where she oversaw medical affairs, public health initiatives,
science, and policy. Before this role, she held various leadership
positions including President and Board Chair of the American
Academy of Family Physicians, Pennsylvania Physician General,
President of the Strategic Health Institute, and Board Director at
Capitol Blue Cross. Additionally, she holds current board positions
at Traditions Bank and Telligen.
Dr. Filer's appointment reflects Pelvital's devotion to
assembling a diverse and accomplished Board of Directors to usher
the company on an exciting phase of innovation, increased
visibility, and market access expansion.
About Pelvital
Pelvital USA, Inc. is a women's
health medical device company empowering women and clinicians to
restore pelvic health with effective, convenient products backed by
strong clinical evidence. Their first product, Flyte®, is an
FDA-cleared novel in-home treatment for stress urinary incontinence
and weakened pelvic floor muscles. Flyte is the first and only
in-home product to deliver the therapeutic treatment modality of
mechanotherapy to the pelvic floor. Mechanotherapy is a
well-established treatment modality that stimulates tissue
regeneration and the creation of neuromuscular memory. Learn more
at flytetherapy.com.
Media Contact
Christine Joyce, Pelvital, 1
2015720089, flyte@victorypublicrelations.com
View original content to download
multimedia:https://www.prweb.com/releases/pelvital-appoints-dr-wanda-filer-to-its-board-of-directors-302140105.html
SOURCE Pelvital